|
WO2021000013A1
|
|
Compositions and methods of use
|
|
WO2020237306A1
|
|
Methods for modulating t cell activation
|
|
WO2020124136A1
|
|
Methods of treating inflammation
|
|
WO2020087126A1
|
|
Methods of treatment, prevention and diagnosis
|
|
WO2020176921A1
|
|
Immunosuppressive glycoforms of soluble cd52
|
|
US2020281223A1
|
|
Purification method
|
|
AU2019201465B1
|
|
Purification method
|
|
PH12019500090A1
|
|
Insulin analogs
|
|
WO2019018890A1
|
|
Novel spirocyclic compounds
|
|
EP3585888A1
|
|
A malaria vaccine and methods for producing same
|
|
AU2017393085A1
|
|
System, method, apparatus and diagnostic test for Plasmodium vivax
|
|
AU2017298565A1
|
|
Insulin analogs
|
|
CN108778314A
|
|
To the inhibition of the SH2 albumen of cytokine induction in NK cells
|
|
AU2014280992A1
|
|
Novel Anti-Cancer Agents
|
|
NZ714347A
|
|
Method of treating intracellular infection
|
|
AU2014202830A1
|
|
Bak binding proteins
|
|
CA2804648A1
|
|
Protein kinase inhibitors and methods of treatment
|
|
AU2010268756A1
|
|
Sulfated polysaccharides having antiplasmodial activity and methods and products for identifying antiplasmodial activity
|
|
AU2010244972A1
|
|
Modulation of inducible nitric oxide (iNOS) binding to SPRY domain-containing SOCS-box peptides (SSB)
|
|
AU2010239125A1
|
|
Structure of the C-terminal region of the insulin receptor alpha-chain and of the insulin-like growth factor receptor alpha-chain
|
